92 results
424B5
RDHL
Redhill Biopharma Ltd.
2 Apr 24
Prospectus supplement for primary offering
4:05pm
are expected in the coming weeks. The primary endpoint of the trial is the proportion of patients breathing room air without oxygen support by Day 14 … % of patients treated with opaganib (n=22) reached room air by Day 14 compared to 22.2% in the placebo group (n=18). The benefit of reaching room air
6-K
RDHL
Redhill Biopharma Ltd.
20 Feb 24
Current report (foreign)
7:01am
, inflammation in the lungs can cause the tissue around the air sacs of the lungs (alveoli) to become damaged, thickened, and scarred – this is known as pulmonary
424B5
RDHL
Redhill Biopharma Ltd.
26 Jan 24
Prospectus supplement for primary offering
9:29am
in the coming weeks. The primary endpoint of the trial is the proportion of patients breathing room air without oxygen support by Day 14. Additional important … treated with opaganib (n=22) reached room air by Day 14 compared to 22.2% in the placebo group (n=18). The benefit of reaching room air by Day 14
424B5
RDHL
Redhill Biopharma Ltd.
25 Jul 23
Prospectus supplement for primary offering
8:00am
of the trial is the proportion of patients breathing room air without oxygen support by Day 14. Additional important outcome measures, such as time … room air by Day 14 compared to 22.2% in the placebo group (n=18). The benefit of reaching room air by Day 14 for patients on opaganib was maintained
424B5
05m8cu1dcf4
3 Apr 23
Prospectus supplement for primary offering
8:49am
424B5
o0egq6lu37q1u2 1yh1m
6 Dec 22
Prospectus supplement for primary offering
6:04am
6-K
EX-1.1
7dgvz
5 Dec 22
Current report (foreign)
4:24pm
424B5
69b8b zxqh5pkg0
2 Dec 22
Prospectus supplement for primary offering
6:31am
6-K
EX-99.1
913hlheo89fpb9t01ix
19 Oct 22
RedHill’s Oral Broad-Acting Antiviral, Opaganib, Granted
7:04am
424B5
rpjmqqb
11 May 22
Prospectus supplement for primary offering
8:47am
6-K
EX-99.1
kthzc
7 Feb 22
Current report (foreign)
10:17am
6-K
EX-99.1
igl6 0a5tw
13 Jan 22
RedHill Biopharma’s Oral Opaganib Significantly Improves
10:38am
6-K
EX-99.1
grhlraarknai4t9a7y3
6 Dec 21
RedHill Biopharma Reports that Opaganib Mechanism Not
7:04am
6-K
EX-99.1
fnrrort8c0r
30 Nov 21
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
7:01am
6-K
EX-1.1
jenjtqcj0hw71 vzl
22 Nov 21
Current report (foreign)
4:54pm
424B5
5i51u m08a1dn18w
22 Nov 21
Prospectus supplement for primary offering
4:30pm
424B5
pb666y
18 Nov 21
Prospectus supplement for primary offering
4:17pm